Branched Chain Amino Acid Transaminase (BCAT)

Branched Chain Amino Acid Transaminase (BCAT) is a key enzyme regulating the initial catabolism of branched-chain amino acids (BCAAs: leucine, isoleucine, and valine). It catalyzes the first, reversible transamination step that converts BCAAs into their corresponding α-keto acids (BCKAs).
There are two isoforms of BCAT: the cytosolic form (BCATc or BCAT1) and the mitochondrial form (BCATm or BCAT2). BCAT1 is mainly expressed in the brain and immune cells (such as activated T lymphocytes and macrophages), while BCAT2 is widely expressed in tissues such as skeletal muscle, kidney, pancreas, stomach, and colon. Unlike most amino acids, the initial site of BCAA catabolism is skeletal muscle rather than the liver, due to the low hepatic BCAT activity.
The primary functions of BCAT include regulating protein synthesis (via activation of the mTOR pathway), maintaining glucose homeostasis, participating in neurotransmitter synthesis, modulating immune responses, and contributing to energy metabolism. Leucine, in particular, serves as a potent metabolic signal that directly or indirectly activates the mTORC1 pathway, thereby affecting cell growth, autophagy, and insulin signaling.
Dysregulation of BCAT is closely associated with various diseases. Congenital defects in BCAT can cause maple syrup urine disease (MSUD). In addition, BCAT expression and activity are often altered in conditions such as type 1 and type 2 diabetes, obesity, and insulin resistance, leading to abnormal BCAA levels and contributing to lipid accumulation and metabolic disturbances. Moreover, BCAT1 is upregulated in multiple cancer types, where it contributes to metabolic reprogramming and promotes tumor growth and invasiveness. Altered BCAT expression is also implicated in Alzheimer’s disease, heart failure, and hepatic and renal disorders.
Thus, BCAT is not only a critical node in BCAA metabolism but is also closely involved in the development and progression of many chronic diseases, making its metabolic regulatory mechanisms an important subject of study[1][2].

共 2种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
Sodium α-ketoisocaproate
Sodium 4-methyl-2-oxopentanoate; 2-Ketoisocaproic acid sodium salt

Sodium α-ketoisocaproate(Sodium 4-methyl-2-oxopentanoate)是一种胰岛素促分泌剂,可在 BCAT 和 BCATm 的催化下发生转氨基反应生成 α-酮戊二酸和亮氨酸,还能结合 SUR1 位点以抑制 KATP 通道活性而不直接影响 Kir6.2 亚基,并调控 Ca2+ 内流,从而在胰岛以及 BCATm 表达充足的完整小鼠胰腺中发挥促胰岛素活性,可用于 2 型糖尿病的相关研究。

4502-00-5
Substrate
98.0%
Sodium α-ketoisocaproate
Platycodin D3
桔梗皂苷 D3

Platycodin D3 是一种存在于桔梗 (Platycodon grandiflorum) 中的三萜皂苷,具有抗炎、调节气道黏液分泌、改善哮喘气道炎症与重构以及抑制丙肝病毒 (HCV) 复制等多种活性,其对 HCV NS5B RNA 依赖的 RNA 聚合酶的 IC50 为 8 μg/mL,可用于哮喘、丙型肝炎病毒感染及炎症性疾病的相关研究。

67884-03-1
Inducer
98.91%
桔梗皂苷 D3

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础